Pharma Globenewswire

Global Cataract Surgery Devices Market to Grow at a CAGR of 5.07% by 2032 | DelveInsight

19 November 2025

According to DelveInsight’s analysis, the growth of the Cataract Surgery Devices Market is primarily driven by the rising prevalence of cataracts and vision impairment, increased incidence of lifestyle-related conditions contributing to cataract development, the expanding geriatric population, and accelerated product development initiatives

Uncategorised

Marginal Zone Lymphoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape | DelveInsight

19 November 2025

Marginal Zone Lymphoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Beigene, InnoCare Pharma, Hutchmed, Incyte, Innovent, MorphoSys, Beijing Mabworks Biotech (Las Vegas, Nevada, United States) As per DelveInsight’s evaluation, globally, the Marginal Zone Lymphoma (MZL)

Uncategorised

Clostridium Difficile Infections Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies | DelveInsight

19 November 2025

As per DelveInsight’s latest evaluation, the global Clostridium Difficile Infections therapeutic pipeline includes 20+ active companies involved in advancing 22+ CDI treatment candidates, covering clinical trials, therapeutic approaches, mechanisms of action, routes of administration, and key ongoing developments. The “Clostridium Difficile Infections

Market Insights

EGFR Inhibitor Market Expected to Gain Momentum Through 2034 | DelveInsight

19 November 2025

DelveInsight’s “EGFR Inhibitor Market Insights, Epidemiology, and Market Forecast-2034” report provides an in-depth analysis of the EGFR Inhibitor market, including historical and projected epidemiology trends, as well as market dynamics across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom,

Market Insights

Myelofibrosis Market Poised to Expand Significantly at 9% CAGR from 2025 to 2034 | DelveInsight

19 November 2025

The introduction of novel therapies, including BESREMi (PharmaEssentia/AOP Orphan Pharmaceuticals), INCB057643 (Incyte), XPOVIO (Karyopharm Therapeutics), RYTELO (Geron), REBLOZYL (Bristol Myers Squibb), Navtemadlin (Kartos Therapeutics), Pelabresib (Novartis), among others, is poised to reshape the myelofibrosis treatment landscape. DelveInsight’s Myelofibrosis Market Insights report includes

Market Insights

KRAS Inhibitors Market Set for Breakneck 35% CAGR Growth by 2034 | DelveInsight

19 November 2025

The KRAS inhibitors market is projected to witness strong expansion, fueled by the growing burden of cancer, wider access to advanced therapies, and a promising pipeline featuring candidates such as Olomorasib (Eli Lilly), MK-1084 (Merck/Taiho/Astex Pharmaceuticals), Divarasib (Roche), Daraxonrasib (Revolution Medicines), Onvansertib

Market Insights

Niemann-Pick Type C Market Poised for Strong 14.8% CAGR Growth (2025–2034) | DelveInsight

19 November 2025

The NPC market remains constrained by the scarcity of approved therapies and a substantial unmet medical need. Nonetheless, upcoming treatments, including Cyclo Therapeutics’ Trappsol Cyclo, Azafaros’ oral small-molecule nizubaglustat (AZ-3102), and the early-stage candidate Adrabetadex (VTS-270), combined with increasing disease awareness, are

News

NCFB Market on the Brink of Change as First DPP1 Inhibitor Marks Approval | DelveInsight

19 November 2025

The NCFB market is entering a new phase as Insmed’s BRINSUPRI has achieved a major regulatory breakthrough, securing FDA approval as the first therapy and the first-ever DPP1 inhibitor. DelveInsight’s Non-cystic Fibrosis Bronchiectasis Market Report 2034 includes a comprehensive understanding of current

Market Insights

Triple-Negative Breast Cancer Market to Showcase Growth at 4.7% CAGR Through 2034 | DelveInsight

19 November 2025

The TNBC market is projected to expand, driven by rising disease prevalence, advances in targeted treatment options, and the introduction of new therapies, including DATROWAY [(Datopotamab Deruxtecan), AstraZeneca and Daiichi Sankyo], IMFINZI [(Durvalumab), AstraZeneca], PADCEV [(Enfortumab vedotin), Astellas Pharma and Pfizer], Tilarginine

Latest

Global Cataract Surgery Devices Market to Grow at a CAGR of 5.07% by 2032 | DelveInsight

Marginal Zone Lymphoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape | DelveInsight

Clostridium Difficile Infections Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies | DelveInsight

EGFR Inhibitor Market Expected to Gain Momentum Through 2034 | DelveInsight

Myelofibrosis Market Poised to Expand Significantly at 9% CAGR from 2025 to 2034 | DelveInsight

KRAS Inhibitors Market Set for Breakneck 35% CAGR Growth by 2034 | DelveInsight

Niemann-Pick Type C Market Poised for Strong 14.8% CAGR Growth (2025–2034) | DelveInsight

NCFB Market on the Brink of Change as First DPP1 Inhibitor Marks Approval | DelveInsight

Triple-Negative Breast Cancer Market to Showcase Growth at 4.7% CAGR Through 2034 | DelveInsight

Recent Posts

Recent Comments

Hi There!

Banner

Latest Interviews

Newsletter

Authors